Author: Ben Rogers
Simple Food Change Could Help Prevent Crohn’s Disease
New research following 220,000 women for 25 years found that eating more fermentable fiber significantly reduced the risk of developing Crohn’s disease. This offers hope for IBD prevention through accessible dietary changes like adding beans, oats, and bananas to family meals.
New Treatment Shows Promise Across Multiple Inflammatory Diseases
Merck expands tulisokibart trials beyond IBD to include multiple inflammatory conditions, offering new hope for comprehensive treatment approaches. This promising research targets the root causes of inflammation across different diseases.
New Oral Pill Shows Promise for Ulcerative Colitis Relief
New research on an oral medication called icotrokinra shows promising results for ulcerative colitis treatment, with clinical remission rates reaching 30.2% in Phase 2 trials. This once-daily pill represents a potential game-changer for patients seeking more convenient treatment options.
New Crohn’s Treatment Shows Promise in Major Clinical Trials
New clinical trials testing guselkumab for Crohn’s disease are showing promising results, with over half of participants achieving clinical remission and reduced steroid dependence. These studies signal a shift toward treatments that aim for both symptom relief and true intestinal healing.
New Hope in Gastroenterology: Why 2025’s Breakthroughs Matter
Q3 2025 brought major advances in gastroenterology, from breakthrough cancer immunotherapies to improved Barrett’s esophagus care. Here’s why these developments matter for the IBD community and what they mean for the future of digestive health treatment.
The Hidden Strength of Moms Living with Crohn’s Disease
Motherhood with Crohn’s disease brings unique challenges that extend far beyond typical IBD symptoms. From reproductive health concerns to fertility planning, mothers with Crohn’s navigate complex decisions while caring for their families.
New Hope: Switching Infliximab Delivery Could Change IBD Life
New research shows IBD patients can successfully switch from IV to subcutaneous infliximab while maintaining remission, with over 95% staying in remission for at least one year. This could transform treatment by offering more convenience and flexibility without sacrificing effectiveness.
Green Bay’s Walk Shows How Community Support Heals IBD Isolation
The Green Bay Take Steps Walk demonstrates how community support can combat the isolation that often accompanies IBD. Beyond fundraising for research, these events create vital connections that address the psychological challenges of living with chronic illness.
IBD Treatment Revolution: $34B Market Growth Brings New Hope
The IBD treatment market is projected to grow from $23 billion to $34 billion by 2033, driven by breakthrough biologics, precision medicine, and nanotechnology-based therapies. This unprecedented growth signals real hope for better quality of life and long-term remission for millions living with Crohn’s disease and ulcerative colitis.
Finding Hope: Michigan Medicine’s Whole-Person IBD Care Approach
University of Michigan Health’s IBD Program takes a revolutionary whole-person approach to Crohn’s and colitis care, integrating gastroenterology, surgery, nutrition, and mental health support. This comprehensive model represents a significant shift toward treating not just the disease, but the entire person living with IBD.
